Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AH005
- Development stage
- Preclinical
- Lead developer
- Apricity Health
01
Overview
AH005 is a preclinical-stage precision oncology candidate being developed by Apricity Health. It is part of a pipeline of therapies specifically designed for cancer patients who do not respond to existing standard-of-care treatments. The development of AH005 utilizes Apricity Health's proprietary approach of identifying 'Target Box Pairs' from real-world data to discover new therapies directed at targets driving drug resistance. The program incorporates blood-based biomarkers for patient selection and is intended for development within a precision clinical trial framework. As of the current pipeline status, AH005 is undergoing preclinical validation.
Beyond the preview
Go deeper on AH005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AH005.